Transforming the treatment of cancer
IL-2 based strategies for cancer immunotherapy
Innovative, safe and highly effective therapeutics that address today’s cancer treatment challenges.
IL-2 induces expansion of T cells and NK cells and promotes a cytotoxic T cell-mediated anti-tumor response
IL-2 mediates complete and durable regression of metastatic disease in a small percentage of RCC and melanoma patients. Proleukin® was approved for metastatic renal cell carcinoma in 1992 and for metastatic melanoma in 1998.
Our strategy
Twain therapeutics technology is based on antibody based IL-2 receptor agonists.
This approach increases the half-life of the therapeutic, which ultimately increases the therapeutic index and reduces the likelihood of side effects. Our TRON molecules are targeted to amplify CD8 & NK cell responses, whilst minimising Tregs & endothelial cells.
IL-2 Therapies
IL-2 mediates complete and durable regression of metastatic disease in a small percentage of RCC and melanoma patients.
News & Updates
As we work on our capabilities and technology, we aim to update you with our latest development.
Watch this space for updates!